UNICREDIT BANK/CALL/CARL ZEISS MEDITEC/125/0.1/18.09.24 Stock

Warrant

DE000HD4U3J0

Market Closed - BOERSE MUENCHEN 07:47:01 2024-05-31 EDT
0.018 EUR +1,700.00% Intraday chart for UNICREDIT BANK/CALL/CARL ZEISS MEDITEC/125/0.1/18.09.24
1 month-89.41%
Date Price Change
24-05-31 0.018 +1,700.00%
24-05-30 0.001 -.--%
24-05-29 0.001 -.--%
24-05-28 0.001 -85.71%
24-05-27 0.007 -84.78%

Real-time BOERSE MUENCHEN

Last update May 31, 2024 at 07:47 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying CARL ZEISS MEDITEC AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD4U3J
ISINDE000HD4U3J0
Date issued 2024-04-18
Strike 125
Maturity 2024-09-18 (108 Days)
Parity 10 : 1
Emission price 0.17
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.22
Lowest since issue 0.001
Delta0x
Omega 0.000000
Premium0x
Gearing0x
Moneyness 0.6896
Difference Strike 40.35
Difference Strike %+32.28%
Intrinsic value 0.000000

Company Profile

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
Sector
-
More about the company

Ratings for Carl Zeiss Meditec AG

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Carl Zeiss Meditec AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
84.65 EUR
Average target price
103.9 EUR
Spread / Average Target
+22.70%
Consensus